Description
Phospho-Jak1 (Tyr1034/1035) Rabbit APC Conjugate
| Catalog number: | B2018839 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 10 ug |
| Molecular Weight or Concentration: | N/A |
| Supplied as: | Solution |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 2-8C |
| Keywords: | Tyrosine-protein kinase JAK1, Janus kinase 1 |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, Quaglino P, Zalaudek I, Marzano AV, Ribero S, Alberti-Violetti S. Topical ruxolitinib: A new treatment for vitiligo J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2222-2230.
- Kikkawa K, Matsuda T, Fujimuro M, Sekine Y. The Atypical Dual Specificity Phosphatase DUSP15 Regulates Jak1-Mediated STAT3 Activation Biol Pharm Bull. 2024;47(9):1487-1493.
- Pardanani A, Gotlib J, Roberts AW, Wadleigh M, Sirhan S, Kawashima J, Maltzman JA, Shao L, Gupta V, Tefferi A. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis Leukemia. 2018 Apr;32(4):1035-1038.
- Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis Future Oncol. 2011 Sep;7(9):1035-43.
- Sk MF, Jonniya NA, Roy R, Kar P. Phosphorylation-Induced Conformational Dynamics and Inhibition of Janus Kinase 1 by Suppressors of Cytokine Signaling 1 J Phys Chem B. 2022 May 5;126(17):3224-3239.
- Runtsch MC, Angiari S, Hooftman A, Wadhwa R, Zhang Y, Zheng Y, Spina JS, Ruzek MC, Argiriadi MA, McGettrick AF, Mendez RS, Zotta A, Peace CG, Walsh A, Chirillo R, Hams E, Fallon PG, Jayamaran R, Dua K, Brown AC, Kim RY, Horvat JC, Hansbro PM, Wang C, ONeill LAJ. Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages Cell Metab. 2022 Mar 1;34(3):487-501.e8.
- Pan Y, Shu G, Fu L, Huang K, Zhou X, Gui C, Liu H, Jin X, Chen M, Li P, Cen J, Feng Z, Lu J, Chen Z, Li J, Xu Q, Wang Y, Liang H, Wang Z, Deng Q, Chen W, Luo J, Yang J, Zhang J, Wei J. EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1 Adv Sci (Weinh). 2023 Apr;10(11):e2206792.
- Heuschkel MJ, Bach C, Meiss-Heydmann L, Gerges E, Felli E, Giannone F, Pessaux P, Schuster C, Lucifora J, Baumert TF, Verrier ER. JAK1 promotes HDV replication and is a potential target for antiviral therapy J Hepatol. 2024 Feb;80(2):220-231.
- Abreu MT. JAK1 Inhibition to Treat Crohns Disease N Engl J Med. 2023 May 25;388(21):2005-2009.
